Abstract
Allergologie select, Vol. 8/2024 (270-277)
Protocol for the systematic reviews on the desirable and undesirable effects of pharmacological treatments of allergic rhinitis informing the ARIA 2024 guidelines
Rafael José Vieira1,2, Maria Inês Torres1,2, Antonio Bognanni3,4, Sara Gil-Mata1,2, Renato Ferreira-da-Silva1,2, Nuno Lourenço-Silva1,2, António Cardoso-Fernandes1,2, André Ferreira2,5,6, Henrique Ferreira-Cardoso1,2, João Teles1,2, Miguel Campos-Lopes1,2, João A. Fonseca1,2, Juan José Yepes-Nuñez3,7, Ludger Klimek8,9, Torsten Zuberbier10,11, Holger Schünemann3, Jean Bousquet10,11,12, and Bernardo Sousa-Pinto1,2
1MEDCIDS – Department of Community Medicine, Information and Health Decision Sciences, 2CINTESIS@RISE – Health Research Network, MEDCIDS, Faculty of Medicine, University of Porto, Porto, Portugal, 3Department of Health Research Methods, Evidence and Impact, 4Department of Medicine, Evidence in Allergy Group, McMaster University, Hamilton, ON, Canada, 5Unit of Anatomy, Department of Biomedicine, Faculty of Medicine, University of Porto, 6Department of Ophthalmology, Centro Hospitalar Universitário do Porto, Porto, Portugal, 7School of Medicine, Universidad de los Andes, Bogotá, Colombia, 8Department of Otolaryngology, Head and Neck Surgery, Universitätsmedizin Mainz, Mainz, 9Center for Rhinology and Allergology, Wiesbaden, 10Institute of Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 11Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany, and 12ARIA, Montpellier, France
There is insufficient evidence regarding the comparative efficacy and safety of pharmacological treatments of allergic rhinitis (AR). In the context of informing the 2024 revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, we plan to perform three systematic reviews of randomized controlled trials (RCTs) comparing the desirable and undesirable effects (i) between intranasal and oral medications for AR; (ii) between combinations of intranasal and oral medications versus nasal or oral medications alone; and (iii) among different intranasal specific medications. We will search four electronic bibliographic databases and three clinical trials databases for RCTs examining patients ≥ 12 years old with seasonal or perennial AR. Assessed outcomes will include the Total Nasal Symptom Score, the Total Ocular Symptom Score, and the Rhinoconjunctivitis Quality-of-Life Questionnaire. We will assess the methodological quality of included primary studies by using the Cochrane risk-of-bias tool. If appropriate, we will perform a pairwise random-effects meta-analysis for each pair of assessed medication classes and outcomes, as well as a network meta-analysis to assess the comparative efficacy of intranasal medications among each other. Heterogeneity will be explored by sensitivity and subgroup analyses. This set of systematic reviews will allow for a comprehensive assessment of the effectiveness and safety of pharmacological interventions for AR and inform recommendations in the context of the ARIA guidelines.Correspondence to:
Professor Jean Bousquet, Institute of Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
Email: [email protected]
